{"news_desk": "Business", "print_page": "1", "section_name": "Technology", "subsection_name": null, "document_type": "article", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/01/19/business/pharmajump3/pharmajump3-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/01/19/business/pharmajump3/pharmajump3-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnail": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2015/01/19/business/pharmajump3/pharmajump3-thumbStandard.jpg"}], "abstract": "Biotech industry is riding unprecedented wave of soaring stock prices and high rate of drug approvals, but executives and investors remain divided in their opinion of its future; some argue that industry has turned a corner in which high failure rate of new drugs has permanently declined, and that Big Pharma is set to take on new set of illnesses for first time; others remain skeptical, citing imminent bubble.", "type_of_material": "News", "word_count": "1441", "lead_paragraph": "Soaring stock prices and major advances in fighting diseases have some saying the industry has turned a corner and others watching for a bursting bubble.", "pub_date": "2015-01-19T00:00:00Z", "_id": "54bc59d138f0d86e1bcc8b52", "byline": {"contributor": "", "original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "source": "The New York Times", "snippet": "Soaring stock prices and major advances in fighting diseases have some saying the industry has turned a corner and others watching for a bursting bubble.", "web_url": "http://www.nytimes.com/2015/01/19/technology/riding-high-biotech-firms-remain-wary.html", "slideshow_credits": null, "blog": [], "keywords": [{"rank": "1", "is_major": "Y", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "11", "is_major": "N", "value": "Biogen Idec Inc", "name": "organizations"}, {"rank": "12", "is_major": "N", "value": "bluebird bio Inc.", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Stocks and Bonds", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "JPMorgan Chase & Company", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Vertex Pharmaceuticals Inc", "name": "organizations"}, {"rank": "8", "is_major": "N", "value": "Juno Therapeutics Inc", "name": "organizations"}, {"rank": "9", "is_major": "N", "value": "ZIOPHARM Oncology Inc", "name": "organizations"}, {"rank": "10", "is_major": "N", "value": "Intrexon Corporation", "name": "organizations"}], "headline": {"main": "Riding High, Biotech Firms Remain Wary", "print_headline": "Riding High, Biotech Firms Remain Wary"}}